Experian shares steady after 19-month low — what the stock is pricing in now

Experian shares steady after 19-month low — what the stock is pricing in now

London, Jan 22, 2026, 09:15 GMT — Regular session

Experian (EXPN.L) shares held steady in early London trading Thursday, edging up roughly 0.1% to 3,072 pence after a steep drop the previous day. The stock moved within a 3,066 to 3,116 pence band. (Google)

Wednesday’s drop felt more like a reaction to impatience than a straightforward earnings miss. Investors were clearly expecting an upgrade to full-year guidance, not a steady forecast. Shares slid to a 19-month low, tumbling as much as 7% after Experian left its annual outlook unchanged. The stock has now fallen roughly 20% over the past year. Andrew Ripper, an analyst at Panmure Liberum, pointed to a weak U.S. dollar, the possibility of new U.S. limits on credit card interest rates, and fresh competition from Fair Isaac as ongoing concerns. (Reuters)

Experian slipped 4.87% to 30.70 pounds on Wednesday, lagging behind a modestly stronger FTSE 100, MarketWatch data shows. (MarketWatch)

The selloff hit despite Experian posting solid momentum in its fiscal third quarter, ending Dec. 31. Revenue climbed 12% on actual exchange rates and 10% at constant currency. Organic revenue — excluding currency effects and acquisitions — rose 8%, with full-year guidance unchanged. CEO Brian Cassin said, “We delivered strong Q3 growth… all in-line with our expectations.” Experian plans to release full-year results on May 20. (Experian)

Jefferies analyst Allen Wells took a cautious stance, noting that “3Q organic revenue growth of 8% is in line with expectations and underlying trends remain solid.” The note also highlighted Experian’s reaffirmation of its FY26 guidance, which anticipates total revenue growth of 11% and organic growth of 8%. The company kept its margin outlook steady, aiming for a 30–50 basis point improvement excluding foreign exchange (a basis point equals one-hundredth of a percentage point). (Advfn)

Investors will be watching closely to see if Wednesday’s selloff reflected positioning rather than underlying fundamentals. Experian’s results hinge on volumes in credit checks, mortgage inquiries, and fraud screenings—all of which can shift rapidly based on lender appetite and policy cues.

The company’s update highlighted strength in North America, but business-to-business growth stalled in Latin America and the UK and Ireland—an indication to some traders that regional performance remains uneven.

Competition is heating up. Fair Isaac’s move to sell credit scores straight to mortgage lenders threatens to cut out the bureaus as middlemen, stirring debate about how much room the sector has left to grow.

The downside is straightforward. Should U.S. lending momentum stall once more, or if policy changes start to hurt card economics, volume-driven revenue risks taking a hit just as the market pushes for upgrades rather than stability.

Traders are now focused on whether Experian can bounce back from Wednesday’s dip without offering new guidance. The key date ahead is May 20, when the full-year results drop—expect any remarks on U.S. consumer credit to influence sentiment long before that.

Stock Market Today

  • Cadence Design Systems (CDNS) Stock Shows 21.5% Upside Potential in Tech Sector
    January 22, 2026, 7:39 AM EST. Cadence Design Systems (NASDAQ: CDNS) holds a market capitalization of $85.52 billion and trades at $313.84, with analysts projecting a 21.50% upside to an average target price of $381.32. The company, serving industries like automotive and 5G, reports a strong return on equity of 21.74% and free cash flow of $1.38 billion. Despite a premium forward P/E ratio of 38.97, Cadence's 10.10% revenue growth supports confidence in its earnings prospects. Technical indicators show the stock trades below key moving averages with a bearish sentiment, possibly indicating undervaluation. Cadence's advanced tech solutions and growth focus position it as a promising stock for investors seeking exposure in the competitive technology sector.
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk
Previous Story

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

Lloyds shares are above £1 again — UBS lifts target as investors do the dividend maths
Next Story

Lloyds shares are above £1 again — UBS lifts target as investors do the dividend maths

Go toTop